Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Form 8.3 - LondonMetric Property plc
-
Wearable Devices Releases Mudra Developer Kit for Its Gesture Control Technology
-
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
-
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
-
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
-
Revoltz Opens for Pre-Orders of its Revolutionary Micro Mobility EV
-
Form 8.3 - Dechra Pharmaceuticals PLC
-
OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company
-
Form 8.3 - ABRDN European Logistics Income PLC
-
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Hemlo Explorers Provides Further Update on Pic Project Option
-
Sibros Accelerates the Future of SDV Innovation at CES 2024
-
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
-
The Simply Good Foods Company Reports Fiscal First Quarter 2024 Financial Results and Reaffirms Full Fiscal Year 2024 Net Sales and Adjusted EBITDA Outlook
-
Kick off the New Year with a ‘BOOST’ from RIFF Cannabis
-
Lithium Ionic: 2023 Year in Review and Outlook for 2024
-
Plymouth Industrial REIT Provides Activity Update for Fourth Quarter 2023
-
Liquidity Services Announces First Quarter Fiscal Year 2024 Earnings Conference Call
-
Synlogic Provides Corporate Update and Outlook for 2024
-
Waste Eliminator Announces Opening of its New Material Recovery Facility
-
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
-
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
-
UMH PROPERTIES, INC. CELEBRATES 55th ANNIVERSARY AT THE NEW YORK STOCK EXCHANGE ON JANUARY 10, 2024
-
Marathon Digital Holdings Announces Bitcoin Production and Mining Operation Updates for December 2023
-
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
-
Bitfarms to Present at the 26th Annual Needham Growth Conference
-
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
-
Carbon Streaming Announces Reduction in Board Size
-
Mattermost enhances self-sovereign Skype for Business alternative to address Schrems II requirements with connectivity to Pexip and Microsoft Teams
-
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
-
CECO Environmental to Present at the 26th Annual Needham Growth Conference on January 17
-
Kick off the New Year with a ‘BOOST’ from RIFF Cannabis
-
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
-
Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing
-
TRU Staffing Partners Named Finalist in Legalweek Leaders in Tech Law Innovation Awards
-
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
-
Notice on Additional Manager Engaged and Amended Final Terms of the Third Tranche
-
Stuart Quin joins GHO Capital as Partner
-
ADC Therapeutics Provides Business Updates
-
Versius customer reach increases as CMR Surgical closes 2023 with strongest quarter on record
-
Development Bank of Japan invests in 4BIO Capital’s Ventures III fund
-
Luminosity Gaming Kicks Off 2024 with Luminosity Makes BIG Moves New York
-
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
-
New Era Helium Corp. to List on NASDAQ Through Merger with Roth CH Acquisition V Co.
-
Lands’ End Launches Exclusive Women’s Swimwear Collection at Target
-
DSM: Net Asset Value(s)
-
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
-
Net Asset Value(s)
-
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
